Up to one in four infants globally suffer from excessive crying and fussing – often called colic. A new study shows that the BB-12® probiotic strain may help reduce crying duration and the number of crying episodes and bring relief to infants and their parents
A new three-strain probiotic blend from Chr. Hansen can help support the health and development of intestines in preterm babies and has been shown to reduce risk of Necrotizing enterocolitis by 50%
Global platform brings together the top 100 business leaders who are combining profit and purpose to help achieve the UN Sustainable Development Goals
Despite more challenging growth conditions Chr. Hansen delivers a strong EBIT margin and a healthy cash flow, while also making significant progress on key strategic priorities
A new 10-year agreement enables Chr. Hansen Denmark to switch 100% to green power from two brand new solar parks. The agreement underlines Chr. Hansen’s commitment to a sustainable future and will create more green energy capacity to the benefit of all of Denmark.
En ny tiårig aftale med Better Energy betyder, at Chr. Hansen kan overgå 100% til grøn strøm fra to helt nye solcelleparker. Aftalen understreger Chr. Hansens dedikation til en bæredygtig fremtid og skaber mere grøn energi til hele Danmark.
Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.
Den globale bioscience virksomhed udvider og styrker forskning- & udviklingsfaciliteterne i Hørsholm for at imødekomme den stigende efterspørgsel efter naturlige og bæredygtige produkter.
Global bioscience company Chr. Hansen to expand and strengthen its research & development facilities north of Copenhagen to meet the increasing demand for natural and sustainable products.
En ny sundhedsøkonomisk undersøgelse har påvist, at indtagelsen af probiotika kan bidrage til at reducere omkostningerne forbundet med influenza-lignende sygdom. Alene i USA kan indtagelsen af probiotika nedbringe antallet af sygedage med over 54 millioner dage om året, ifølge undersøgelsen.